Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology Association (EHA).

15^th annual International Congress on Systemic Lupus Erythematosus/43^rd KCR Annual Scientific Meeting
Date/Time: May 20, 2023 at 14:30 - 15:30 KST
Presentation Title: A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus
Poster Number: LSO-090
Session Name: Short Oral Presentation Session 16, SLE Treatment 2
Location: Conference Room 205 B, COEX Convention Center, Seoul, South Korea

EULAR
Date/Time: June 1, 2023 at 12:00-13:30 CEST
Poster Title: A Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, for the Treatment of Systemic Lupus Erythematosus and Other B Cell-Related Disorders (RUBY-1)
Poster Number: POS0114
Session Name: A novel journey into SLE, Sjögren's and APS
Location: Poster Tour Auditorium 12, MiCo Convention Center, Milan, Italy

EHA
Date/Time: June 10, 2023 at 16:30 - 17:45 CEST
Poster Title: Povetacicept (ALPN-303), A Potent Dual BAFF/APRIL Antagonist, for the Treatment of Autoimmune Cytopenias and Other Antibody-Related Diseases
Presentation ID: S276
Session Name: s441 Translational research in rare anemias
Location: Panorama 2, Congress Centre, Forum, Festhalle and Halls 1 and 3 of Messe Frankfurt, Frankfurt, Germany

European Renal Association (ERA)
Date/Time: June 17, 2023 at 17:00 - 18:15 CEST
Presentation Title: Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Povetacicept for Autoimmune Glomerulonephritides
Session Name: The ANCA Vasculitis Variety Session
Location: Amber 3 & 4, MiCo, Milan Convention Centre, Milan, Italy

About Povetacicept (ALPN-303) and the RUBY-1 Phase 1 Study

Povetacicept (ALPN-303) is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in the activation and survival of B cells, particularly antibody-secreting cells. Based upon an engineered TACI (transmembrane activator and CAML interactor) domain, povetacicept exhibits greater potency in preclinical studies versus wild-type TACI-based comparators, as well as other inhibitors of BAFF and/or APRIL alone. Povetacicept is in development for multiple B cell and/or autoantibody-related diseases, such as systemic lupus erythematosus, autoimmune glomerulonephritis, and autoimmune cytopenias.